The artificial intelligence (AI)-powered Neuro Suite reportedly enables radiologists to access leading neurological AI algorithm solutions in the field, including the brain magnetic resonance imaging (MRI) segmentation capabilities of the Combinostics’ algorithm that can help differentiate degenerative pathologies such as Alzheimer’s disease and dementia.
Emphasizing timely neurological disease triage and access to “a first-in-class capability and the only open (artificial intelligence) AI architecture” for clinical AI, ConcertAI’s TeraRecon has launched Neuro Suite.
The Neuro Suite platform allows radiologists to access a variety of AI-powered neuroimaging modalities from leading vendors in the neurology field, including Combinostics, Imaging Biometrics and Cercare Medical, according to TeraRecon.
For the diagnosis of degenerative cerebral pathologies including Alzheimer’s disease and dementia, the Combinostics algorithm offers high-quality segmentation of brain magnetic resonance imaging (MRI) to help assess atrophy. TeraRecon said the algorithm from Imaging Biometrics provides radiologists with insights into the blood supply and oxygenation of brain tumors. Access to the proprietary perfusion technology of Cercare Medical enables neurovascular function assessment down to the capillary level, according to TeraRecon.
“We are proud to enhance our neurological offerings beyond TR Neuro to an entire Neuro Suite, extending to our clinician customers an amazing array of tools streamlined into one place and able to be interacted with to help identify and treat critical neurological issues,” said Dan McSweeney, the president of TeraRecon.
(Editor’s note: For related content, see “TeraRecon Launches AI-Driven Neuroimaging Platform” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Systematic Review: PET/MRI May be More Advantageous than PET/CT in Cancer Imaging
July 18th 2024While PET/MRI and PET/CT had comparable sensitivity for patient-level regional nodal metastases and lesion-level recurrence, the authors of a systematic review noted that PET/MRI had significantly higher accuracy in breast cancer and colorectal cancer staging.